Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05794217 · ClinicalTrials.gov registry record
A Multi-Site Leukopak Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives
A clinical trial of Rare Diseases, sponsored by Sanguine Biosciences.
- Recruiting
- Registry status
- 20,000
- Enrollment target
- 1
- Study location
NCT05794217: Recruiting study of Rare Diseases, sponsored by Sanguine Biosciences.
NCT05794217 is a study of Rare Diseases that is actively recruiting participants, run by Sanguine Biosciences. The registered enrollment target is 20,000 participants, above the 14,618-participant average among 7 other Rare Diseases trials with a reported enrollment target (37% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05794217, a study of Rare Diseases, is actively recruiting participants, sponsored by Sanguine Biosciences.
- RECRUITING
- Registry status
- 20,000 participants
- Enrollment target
- 1
- Study location
Study Summary
To collect, preserve, and distribute annotated leukopak biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions. This protocol will be utilized to collect research grade products that are not meant for transfusion.
Primary Outcome
The studies collected biospecimens are white blood cells, specifically leukopaks.
Conditions Studied
Interventions
- BEHAVIORAL This is a non-interventional study
Study Locations (1)
Massachusetts
- Sanguine Biosciences - Waltham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,000 participants |
| Start Date | 2022-09-28 |
| Est. Completion | 2026-12-31 |
What NCT05794217 shows while recruiting
NCT05794217 is an observational study that tracks outcomes without assigning an intervention. Its 20,000 participants enrollment target places it among the larger protocols in the corpus, above the 14,618-participant average among 7 other Rare Diseases trials with a reported enrollment target (37% higher).
The record links to 1 condition, with Rare Diseases appearing as the primary indexed condition, and to 1 intervention - of which This is a non-interventional study is the first listed.
NCT05794217 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05794217 about?
NCT05794217 is a clinical study titled "A Multi-Site Leukopak Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives". To collect, preserve, and distribute annotated leukopak biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions. This protocol wi...
What is the current status of trial NCT05794217?
This trial is currently recruiting. The enrollment target is 20,000 participants. The study started on 2022-09-28. Estimated completion is 2026-12-31.
What conditions does trial NCT05794217 study?
This clinical trial studies the following conditions: Rare Diseases.
What interventions are being tested in trial NCT05794217?
The interventions under investigation include: This is a non-interventional study (BEHAVIORAL).
Who is sponsoring clinical trial NCT05794217?
This trial is sponsored by Sanguine Biosciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05794217 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rare Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)
RECRUITING · Phase 2
-
Longitudinal Studies of Patient With FPDMM
RECRUITING
-
Genetic Study to Determine the Cause of Birth Defects in Newborns in Texas
RECRUITING · NA
-
Baker Gordon Syndrome Natural History Study
RECRUITING
-
UW Undiagnosed Genetic Diseases Program
RECRUITING
-
Epilepsy Learning Healthcare System (ELHS)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
- NCT00830557 · 20,000 participants
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
- NCT00900471 · 20,000 participants
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
- NCT02735707 · 20,000 participants · Phase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI